Traders Are Watching: BP p.l.c. (NYSE:BP), National Bank of Greece (NYSE:NBG), Concert Pharmaceuticals (NASDAQ:CNCE), Apogee Enterprises, (NASDAQ:APOG), Dynavax Technologies Corporation (NASDAQ:DVAX)

BP p.l.c. (NYSE:BP)’s South African unit sold a 25 percent stake in the business to two black-owned partners that will give the new investors voting rights in the oil producer’s local operations. BP p.l.c. (NYSE:BP) in last trading activity moved down -4.69% to close at $39.64. Company weekly performance is -5.10% while its quarterly performance stands at -15.93%. BP p.l.c. (NYSE:BP) is -23.88% away from its 52 week high.

Nomura lowered shares of National Bank of Greece (NYSE:NBG) from a buy rating to a neutral rating in a research report released on Friday morning, TheFlyOnTheWall.com reports. On last trading day National Bank of Greece (ADR) (NYSE:NBG) moved down -0.85% to close at $2.33. Its volatility for the week is 3.40% while volatility for the month is 3.61%. NBG’s sales growth for past 5 years was -5.00% and its EPS growth for past 5 years was -55.23%. National Bank of Greece (ADR) (NYSE:NBG) monthly performance is -8.63%.

Concert Pharmaceuticals (NASDAQ:CNCE) Director Three Arch Management Iv, L.L. unloaded 250,000 shares of the stock in a transaction that occurred on Tuesday, November 18th. On last trading day Concert Pharmaceuticals, Inc. (NASDAQ:CNCE) moved down -0.63% to close at $12.60. Its volatility for the week is 3.42% while volatility for the month is 5.22%. Concert Pharmaceuticals, Inc. (NASDAQ:CNCE) monthly performance is -13.76%.

Apogee Enterprises, Inc. (NASDAQ:APOG) Presented at Goldman Sachs Industrials Conference at 9:20 AM ET On November 12, 2014. Apogee Enterprises, Inc. (NASDAQ:APOG) has 2.20% insider ownership while its institutional ownership stands at 93.00%. In last trading activity company’s stock closed at $45.23.

Dynavax Technologies Corporation (NASDAQ:DVAX) has regained full rights to DV1179, an investigational bifunctional inhibitor of toll-like receptors or TLR 7 and 9, resulting from the expiration of the Research and Development Collaboration and License Agreement with GSK originally executed in 2008. Dynavax Technologies Corporation (NASDAQ:DVAX) in last trading activity decreased -1.59% to close at $14.86. Company weekly performance is 2.41% while its quarterly performance stands at 4.65%. Dynavax Technologies Corporation (NASDAQ:DVAX) is -30.56% away from its 52 week high.

Leave a Reply

Your email address will not be published. Required fields are marked *

*